SG11201808314QA - Compositions and methods for the treatment of wounds, disorders, and diseases of the skin - Google Patents
Compositions and methods for the treatment of wounds, disorders, and diseases of the skinInfo
- Publication number
- SG11201808314QA SG11201808314QA SG11201808314QA SG11201808314QA SG11201808314QA SG 11201808314Q A SG11201808314Q A SG 11201808314QA SG 11201808314Q A SG11201808314Q A SG 11201808314QA SG 11201808314Q A SG11201808314Q A SG 11201808314QA SG 11201808314Q A SG11201808314Q A SG 11201808314QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- street
- san francisco
- skin
- col7a1
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 206010052428 Wound Diseases 0.000 title abstract 3
- 208000027418 Wounds and injury Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000035475 disorder Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 abstract 3
- 241000220010 Rhode Species 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102100024335 Collagen alpha-1(VII) chain Human genes 0.000 abstract 2
- 101000909498 Homo sapiens Collagen alpha-1(VII) chain Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000012217 deletion Methods 0.000 abstract 2
- 230000037430 deletion Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108010017377 Collagen Type VII Proteins 0.000 abstract 1
- 102000004510 Collagen Type VII Human genes 0.000 abstract 1
- 102000011782 Keratins Human genes 0.000 abstract 1
- 108010076876 Keratins Proteins 0.000 abstract 1
- 102100035199 Procollagen glycosyltransferase Human genes 0.000 abstract 1
- 101710102040 Procollagen glycosyltransferase Proteins 0.000 abstract 1
- 101150009795 UL54 gene Proteins 0.000 abstract 1
- 101150081415 UL55 gene Proteins 0.000 abstract 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 abstract 1
- 244000126002 Ziziphus vulgaris Species 0.000 abstract 1
- 230000003190 augmentative effect Effects 0.000 abstract 1
- 230000003436 cytoskeletal effect Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 101150029683 gB gene Proteins 0.000 abstract 1
- 230000001965 increasing effect Effects 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 101710130522 mRNA export factor Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 230000001502 supplementing effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1748—Keratin; Cytokeratin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
- C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
- C12Y114/11004—Procollagen-lysine 5-dioxygenase (1.14.11.4), i.e. lysine-hydroxylase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662320316P | 2016-04-08 | 2016-04-08 | |
| PCT/US2016/068974 WO2017176336A1 (en) | 2016-04-08 | 2016-12-28 | Compositions and methods for the treatment of wounds, disorders, and diseases of the skin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808314QA true SG11201808314QA (en) | 2018-10-30 |
Family
ID=57822104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808314QA SG11201808314QA (en) | 2016-04-08 | 2016-12-28 | Compositions and methods for the treatment of wounds, disorders, and diseases of the skin |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US9877990B2 (es) |
| EP (2) | EP3712273A1 (es) |
| JP (3) | JP6970086B2 (es) |
| KR (1) | KR20180128016A (es) |
| CN (1) | CN109072255A (es) |
| AU (3) | AU2016401692B2 (es) |
| CA (1) | CA3017487A1 (es) |
| CL (3) | CL2018002814A1 (es) |
| CY (1) | CY1123024T1 (es) |
| DK (1) | DK3377637T3 (es) |
| ES (1) | ES2796488T3 (es) |
| HR (1) | HRP20200853T1 (es) |
| HU (1) | HUE049237T2 (es) |
| LT (1) | LT3377637T (es) |
| MX (2) | MX2018012135A (es) |
| PL (1) | PL3377637T3 (es) |
| PT (1) | PT3377637T (es) |
| RS (1) | RS60410B1 (es) |
| SG (1) | SG11201808314QA (es) |
| SI (1) | SI3377637T1 (es) |
| WO (1) | WO2017176336A1 (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107427529A (zh) | 2014-12-26 | 2017-12-01 | 埃莫里大学 | N4‑羟基胞苷和衍生物及与其相关的抗病毒用途 |
| KR20180128016A (ko) * | 2016-04-08 | 2018-11-30 | 크리스탈 바이오테크, 인크. | 피부의 상처, 장애 및 질환의 치료를 위한 조성물 및 방법 |
| WO2018089893A1 (en) * | 2016-11-14 | 2018-05-17 | The Regents Of The University Of Michigan | Compositions and methods for blocking ultraviolet radiation |
| CN110462040A (zh) | 2017-01-10 | 2019-11-15 | 英特拉克森公司 | 通过新基因开关表达系统调节多肽的表达 |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| EP3775236A1 (en) | 2018-04-12 | 2021-02-17 | Krystal Biotech, LLC | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
| KR20210005141A (ko) | 2018-04-27 | 2021-01-13 | 크리스탈 바이오테크, 인크. | 미적 적용을 위한 미용 단백질(들)을 인코딩하는 재조합 핵산 |
| CA3112627A1 (en) | 2018-09-24 | 2020-04-02 | Krystal Biotech, Inc. | Compositions and methods for the treatment of netherton syndrome |
| JP7560449B2 (ja) * | 2018-09-26 | 2024-10-02 | クリスタル バイオテック インコーポレイテッド | 皮膚疾患の治療のための組成物及び方法 |
| AU2020209687A1 (en) * | 2019-01-18 | 2021-07-29 | Osaka University | Composition for use in treating dystrophic epidermolysis bullosa |
| SG11202107969SA (en) * | 2019-02-08 | 2021-08-30 | Krystal Biotech Inc | Compositions and methods for delivering cftr polypeptides |
| AU2020248453A1 (en) * | 2019-03-27 | 2021-10-28 | Phoenix Tissue Repair, Inc. | Systems and methods for producing collagen 7 compositions |
| WO2021046131A1 (en) | 2019-09-03 | 2021-03-11 | Krystal Biotech, Inc. | Compositions and methods for the treatment of congenital ichthyoses |
| CN112724225B (zh) * | 2019-10-28 | 2023-09-26 | 中国医学科学院药物研究所 | 一种角蛋白bd-6、制法和其药物组合物与用途 |
| WO2021127524A1 (en) | 2019-12-20 | 2021-06-24 | Krystal Biotech, Inc. | Compositions and methods for gene delivery to the airways and/or lungs |
| IL307350A (en) | 2021-04-02 | 2023-11-01 | Krystal Biotech Inc | Viral vectors for cancer treatment |
| MX2024004434A (es) | 2021-10-12 | 2024-07-09 | Phoenix Tissue Repair Inc | Terapia de reemplazo de proteínas con colágeno 7. |
| CN117143223B (zh) * | 2022-08-23 | 2024-03-08 | 山西锦波生物医药股份有限公司 | 一种生物合成人体结构性材料的制备方法 |
| US20240342308A1 (en) * | 2023-04-13 | 2024-10-17 | Krystal Biotech, Inc. | Methods and Compositions for Treating Conditions Involving the Eye |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672344A (en) * | 1987-12-30 | 1997-09-30 | The Regents Of The University Of Michigan | Viral-mediated gene transfer system |
| US5658724A (en) | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
| EP0973538B1 (en) * | 1997-04-10 | 2008-03-12 | University of Southern California | Modified proteins which bind extracellular matrix components |
| US5998174A (en) | 1997-05-12 | 1999-12-07 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Multigene vectors |
| GB9715085D0 (en) * | 1997-07-18 | 1997-09-24 | Jahoda Amanda J | Gene therapy vehicle |
| US6106826A (en) * | 1997-12-17 | 2000-08-22 | Wisconsin Alumni Research Foundation | Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy |
| GB9801930D0 (en) * | 1998-01-29 | 1998-03-25 | Univ London | Mutant herpes simplex viruses and uses thereof |
| EP1083951A4 (en) * | 1998-06-12 | 2004-07-07 | Aradigm Corp | METHOD FOR DISCHARGING POLYNUCLEOTIDS IN THE FORM OF AN AEROSOL IN THE RESPIRATION WAY |
| JP2003535565A (ja) | 1998-12-31 | 2003-12-02 | アーチ ディベロプメント コーポレイション | 新生物疾患の治療に有用な組換え単純ヘルペスウイルス |
| US20040214783A1 (en) * | 2002-05-08 | 2004-10-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
| GB9930418D0 (en) * | 1999-12-22 | 2000-02-16 | Neurovex Ltd | Replication incompetent herpes virus vectors |
| AU2001235829A1 (en) * | 2000-03-02 | 2001-09-12 | Isis Innovation Limited | Mutations in spink5 responsible for netherton's syndrome and atopic diseases |
| US6846670B2 (en) * | 2000-11-28 | 2005-01-25 | The University Of Chicago | Genetically engineered herpes virus for the treatment of cardiovascular disease |
| WO2002076216A1 (en) * | 2001-03-27 | 2002-10-03 | Medigene, Inc. | Viral vectors and their use in therapeutic methods |
| JP2005519091A (ja) * | 2002-03-01 | 2005-06-30 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 癌の再発及び転移の予防 |
| US20040253606A1 (en) | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| WO2006002394A2 (en) * | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| AU2005302408B2 (en) * | 2004-10-28 | 2012-08-09 | The Government of the United States of America as represented by the Department of Veterans Affairs | Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain |
| BRPI0519737A2 (pt) * | 2004-12-21 | 2009-01-27 | Musc Found For Res Dev | composiÇÕes e mÉtodos para promover a cura de feridas e a regeneraÇço de tecidos |
| JP2008528508A (ja) * | 2005-01-21 | 2008-07-31 | イントロジェン・セラピューティクス，インコーポレイテッド | 標的細胞の治療および予防核酸への持続性の曝露を可能とする局所投与 |
| EP1885186B1 (en) * | 2005-06-01 | 2015-09-02 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| US8703703B2 (en) * | 2006-12-20 | 2014-04-22 | University Of Central Flordia Research Foundation, Inc. | MCPIP as wound therapy |
| US20080299182A1 (en) * | 2007-03-01 | 2008-12-04 | Shuyuan Zhang | Methods and formulations for topical gene therapy |
| WO2008143875A1 (en) * | 2007-05-14 | 2008-11-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Targeted delivery of glycine receptors to excitable cells |
| WO2009105690A2 (en) * | 2008-02-21 | 2009-08-27 | Targeted Genetics Corporation | Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| CN102458463B (zh) * | 2009-05-22 | 2017-01-18 | 健诺西生物科学公司 | 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法 |
| CN102212559B (zh) | 2011-04-14 | 2014-04-09 | 郑州威瑞生物技术有限公司 | 一种重组的hsv扩增子载体及其用途 |
| WO2013053819A1 (en) * | 2011-10-11 | 2013-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Exon skipping therapy for dystrophic epidermolysis bullosa |
| GB201202561D0 (en) * | 2012-02-15 | 2012-03-28 | Univ Dundee | Treatment of skin disorders |
| AU2013263502B2 (en) * | 2012-05-18 | 2018-02-08 | Otago Innovation Limited | Combination treatments and compositions for wound healing |
| US9393257B2 (en) * | 2013-03-01 | 2016-07-19 | Regents Of The University Of Minnesota | TALEN-based gene correction |
| MX365409B (es) * | 2013-03-14 | 2019-05-31 | Shire Human Genetic Therapies | Composiciones de ácido ribonucleico mensajero del regulador transmembrana de fibrosis quística y métodos y usos relacionados. |
| JP6726824B2 (ja) * | 2013-07-17 | 2020-07-22 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 効率的な遺伝子送達用途のための非毒性ｈｓｖベクター及びその製造のための補完細胞 |
| SG11201603119RA (en) * | 2013-10-28 | 2016-05-30 | Univ Pittsburgh | Oncolytic hsv vector |
| CN105940110A (zh) * | 2014-01-31 | 2016-09-14 | 菲克特生物科学股份有限公司 | 用于核酸产生和递送的方法和产品 |
| GB2526339A (en) * | 2014-05-21 | 2015-11-25 | Imp Innovations Ltd | Lentiviral vectors |
| US20160082129A1 (en) * | 2014-09-24 | 2016-03-24 | Aerpio Therapeutics, Inc. | VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector |
| CA2965770C (en) * | 2014-10-31 | 2024-02-13 | Kyoto Prefectural Public University Corporation | Treatment of cornea using laminin |
| EP3256585A4 (en) * | 2015-02-13 | 2018-08-15 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
| WO2016191684A1 (en) * | 2015-05-28 | 2016-12-01 | Finer Mitchell H | Genome editing vectors |
| CA3008264A1 (en) * | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Gene therapy for ocular disorders |
| KR20180136435A (ko) * | 2016-01-27 | 2018-12-24 | 온코루스, 인크. | 종양 살상형 바이러스 벡터 및 그의 용도 |
| WO2017165806A1 (en) * | 2016-03-25 | 2017-09-28 | Periphagen, Inc. | Hsv vectors for delivery of nt3 and treatment of cipn |
| CN109362223B (zh) * | 2016-03-25 | 2023-08-25 | 普瑞菲根公司 | 高转导hsv载体 |
| KR20180128016A (ko) | 2016-04-08 | 2018-11-30 | 크리스탈 바이오테크, 인크. | 피부의 상처, 장애 및 질환의 치료를 위한 조성물 및 방법 |
| EP3775236A1 (en) | 2018-04-12 | 2021-02-17 | Krystal Biotech, LLC | Compositions and methods for the treatment of autosomal recessive congenital ichthyosis |
| KR20210005141A (ko) | 2018-04-27 | 2021-01-13 | 크리스탈 바이오테크, 인크. | 미적 적용을 위한 미용 단백질(들)을 인코딩하는 재조합 핵산 |
| CA3103374A1 (en) | 2018-06-29 | 2020-01-02 | Krystal Biotech, Inc. | Compositions and methods for antibody delivery |
-
2016
- 2016-12-28 KR KR1020187030112A patent/KR20180128016A/ko not_active Application Discontinuation
- 2016-12-28 US US15/393,151 patent/US9877990B2/en active Active
- 2016-12-28 ES ES16826873T patent/ES2796488T3/es active Active
- 2016-12-28 SI SI201630776T patent/SI3377637T1/sl unknown
- 2016-12-28 HU HUE16826873A patent/HUE049237T2/hu unknown
- 2016-12-28 AU AU2016401692A patent/AU2016401692B2/en active Active
- 2016-12-28 JP JP2018521309A patent/JP6970086B2/ja active Active
- 2016-12-28 LT LTEP16826873.8T patent/LT3377637T/lt unknown
- 2016-12-28 PL PL16826873T patent/PL3377637T3/pl unknown
- 2016-12-28 CN CN201680084419.7A patent/CN109072255A/zh active Pending
- 2016-12-28 CA CA3017487A patent/CA3017487A1/en active Pending
- 2016-12-28 RS RS20200669A patent/RS60410B1/sr unknown
- 2016-12-28 EP EP20161137.3A patent/EP3712273A1/en active Pending
- 2016-12-28 SG SG11201808314QA patent/SG11201808314QA/en unknown
- 2016-12-28 WO PCT/US2016/068974 patent/WO2017176336A1/en active Application Filing
- 2016-12-28 DK DK16826873.8T patent/DK3377637T3/da active
- 2016-12-28 MX MX2018012135A patent/MX2018012135A/es unknown
- 2016-12-28 EP EP16826873.8A patent/EP3377637B1/en active Active
- 2016-12-28 PT PT168268738T patent/PT3377637T/pt unknown
-
2017
- 2017-12-21 US US15/851,488 patent/US10155016B2/en active Active
-
2018
- 2018-10-03 CL CL2018002814A patent/CL2018002814A1/es unknown
- 2018-10-04 MX MX2022006072A patent/MX2022006072A/es unknown
- 2018-10-31 US US16/177,153 patent/US10441614B2/en active Active
-
2019
- 2019-10-10 US US16/598,982 patent/US11185564B2/en active Active
- 2019-12-13 AU AU2019280069A patent/AU2019280069B2/en active Active
-
2020
- 2020-05-27 HR HRP20200853TT patent/HRP20200853T1/hr unknown
- 2020-06-05 CY CY20201100503T patent/CY1123024T1/el unknown
-
2021
- 2021-04-09 CL CL2021000881A patent/CL2021000881A1/es unknown
- 2021-10-27 JP JP2021175260A patent/JP7480105B2/ja active Active
- 2021-11-17 US US17/529,161 patent/US20220273737A1/en not_active Abandoned
-
2022
- 2022-06-30 AU AU2022204729A patent/AU2022204729A1/en active Pending
- 2022-11-30 US US18/060,515 patent/US11865148B2/en active Active
-
2023
- 2023-03-15 CL CL2023000743A patent/CL2023000743A1/es unknown
- 2023-06-27 US US18/342,284 patent/US20230414686A1/en active Pending
- 2023-07-04 JP JP2023109819A patent/JP2023118838A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808314QA (en) | Compositions and methods for the treatment of wounds, disorders, and diseases of the skin | |
| SG11201906301UA (en) | Methods of manufacture of nut flours and formulations for oral immunotherapy | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201907298WA (en) | Methods and compositions for gene transfer across the vasculature | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201810162PA (en) | Polynucleotides encoding citrin for the treatment of citrullinemia type 2 | |
| SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
| SG11201908391XA (en) | Methods for modulating an immune response | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201910096RA (en) | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use | |
| SG11201901020RA (en) | Anti-siglec-7 antibodies for the treatment of cancer | |
| SG11202000263QA (en) | Immunomodulatory retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | |
| SG11201810951RA (en) | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201907934YA (en) | Devices, methods, and compositions useful in cryo-preservation, -storage, -transport, and application of therapeutic mammalian cells | |
| SG11201808306PA (en) | Treatment of cancer with tg02 | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201809100QA (en) | Use of gram negative species to treat atopic dermatitis | |
| SG11201805680SA (en) | Methods and compositions for the treatment of neurologic disease |